THARIMMUNE INC (THAR) Stock Price, Quote, News and Overview
NASDAQ:THAR - Nasdaq - US4327053090 - Common Stock - Currency: USD
THAR Quote, Performance and Key Statistics
1.48
+0.07 (+4.62%)
The current stock price of THAR is 1.48 USD. In the past month the price decreased by -14.45%. In the past year, price decreased by -68.81%.
THAR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 327.88B | ||
| AMGN | AMGEN INC | 13.66 | 152.46B | ||
| GILD | GILEAD SCIENCES INC | 14.36 | 138.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.66 | 65.36B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.19B | ||
| ARGX | ARGENX SE - ADR | 98.97 | 35.47B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.31 | 26.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.10B | ||
| NTRA | NATERA INC | N/A | 21.58B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.47B | ||
| BIIB | BIOGEN INC | 8.39 | 19.45B |
Related stock screener links
About THAR
Company Profile
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Company Info
THARIMMUNE INC
1200 Route 22 East
Bridgewater NEW JERSEY US
Employees: 3
Phone: 13027432995
THARIMMUNE INC / THAR FAQ
What is the stock price of THARIMMUNE INC today?
The current stock price of THAR is 1.48 USD. The price increased by 4.62% in the last trading session.
What is the ticker symbol for THARIMMUNE INC stock?
The exchange symbol of THARIMMUNE INC is THAR and it is listed on the Nasdaq exchange.
On which exchange is THAR stock listed?
THAR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THARIMMUNE INC stock?
7 analysts have analysed THAR and the average price target is 5.1 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 1.48. Check the THARIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THARIMMUNE INC worth?
THARIMMUNE INC (THAR) has a market capitalization of 3.94M USD. This makes THAR a Nano Cap stock.
How many employees does THARIMMUNE INC have?
THARIMMUNE INC (THAR) currently has 3 employees.
What are the support and resistance levels for THARIMMUNE INC (THAR) stock?
THARIMMUNE INC (THAR) has a support level at 1.33 and a resistance level at 1.49. Check the full technical report for a detailed analysis of THAR support and resistance levels.
Should I buy THARIMMUNE INC (THAR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of THAR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of THAR, evaluating the profitability, health, valuation and growth aspects
- THARIMMUNE INC (THAR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THARIMMUNE INC (THAR) Sales and EPS estimates to see what analysts future expectations are.
- THARIMMUNE INC (THAR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THARIMMUNE INC (THAR) Insider and Institutional Ownership to learn about the owners and their transactions.
- THARIMMUNE INC (THAR) Stock Chart to make your own analysis
- THARIMMUNE INC (THAR) Latest news and press-releases to stay up to date.
Does THARIMMUNE INC (THAR) stock pay dividends?
THAR does not pay a dividend.
What is the Price/Earnings (PE) ratio of THARIMMUNE INC (THAR)?
THARIMMUNE INC (THAR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.89).
What is the Short Interest ratio of THARIMMUNE INC (THAR) stock?
The outstanding short interest for THARIMMUNE INC (THAR) is 5.55% of its float. Check the ownership tab for more information on the THAR short interest.
THAR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to THAR. When comparing the yearly performance of all stocks, THAR is a bad performer in the overall market: 89.41% of all stocks are doing better.
THAR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to THAR. The financial health of THAR is average, but there are quite some concerns on its profitability.
THAR Financial Highlights
Over the last trailing twelve months THAR reported a non-GAAP Earnings per Share(EPS) of -9.89. The EPS increased by 94.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.75% | ||
| ROE | -932.83% | ||
| Debt/Equity | 0 |
THAR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to THAR. The Buy consensus is the average rating of analysts ratings from 7 analysts.